推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 近日，海南印發(fā)《海南省醫(yī)療保障局關(guān)于做好2020年擬納入海南基本醫(yī)療保險(xiǎn)用藥范圍的中藥飲片、民族藥品申報(bào)工作的通知》(下簡稱《通知》)，決定自11月17日起至11月30日開啟中藥飲片、民族藥品納入基本醫(yī)療保險(xiǎn)用藥范圍申報(bào)工作。
《通知》要求，中藥飲片、民族藥品范圍包括有國家或地方標(biāo)準(zhǔn)的中藥飲片、中藥配方顆粒，符合國家和海南有關(guān)法律法規(guī)和政策規(guī)定;經(jīng)國家有關(guān)部門批準(zhǔn)上市的民族藥品。
申報(bào)材料主要有：中藥飲片申報(bào)信息包括中藥飲片名稱(藥典或地方標(biāo)準(zhǔn)名稱)、基源、飲片規(guī)格、價(jià)格、標(biāo)準(zhǔn)來源等;中藥配方顆粒申報(bào)信息包括中藥飲片名稱(藥典或地方標(biāo)準(zhǔn)名稱)、基源、規(guī)格、當(dāng)量、價(jià)格、標(biāo)準(zhǔn)來源等;民族藥品申報(bào)信息包括通用名、生產(chǎn)企業(yè)、批準(zhǔn)文號(hào)、劑型、價(jià)格、2018年和2019年使用量。
《通知》明確將會(huì)根據(jù)海南醫(yī)保基金負(fù)擔(dān)能力及用藥需求，經(jīng)相應(yīng)的專家評(píng)審程序，將申報(bào)的中藥飲片、民族藥品納入海南基本醫(yī)療保險(xiǎn)基金支付范圍，并在海南全省各定點(diǎn)醫(yī)療機(jī)構(gòu)發(fā)文執(zhí)行。
